United Therapeutics Co. (NASDAQ:UTHR) Expected to Post Earnings of $3.37 Per Share

Wall Street brokerages expect that United Therapeutics Co. (NASDAQ:UTHR) will announce $3.37 earnings per share (EPS) for the current fiscal quarter, Zacks reports. Five analysts have issued estimates for United Therapeutics’ earnings. The lowest EPS estimate is $3.12 and the highest is $3.85. United Therapeutics posted earnings per share of $3.84 during the same quarter last year, which suggests a negative year-over-year growth rate of 12.2%. The firm is expected to issue its next quarterly earnings results on Wednesday, October 27th.

On average, analysts expect that United Therapeutics will report full year earnings of $11.07 per share for the current financial year, with EPS estimates ranging from $10.47 to $11.88. For the next financial year, analysts forecast that the firm will post earnings of $15.53 per share, with EPS estimates ranging from $11.72 to $17.94. Zacks’ earnings per share averages are an average based on a survey of sell-side analysts that cover United Therapeutics.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, August 4th. The biotechnology company reported $3.65 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.02 by $0.63. United Therapeutics had a net margin of 29.60% and a return on equity of 13.69%. The company had revenue of $446.50 million for the quarter, compared to analyst estimates of $378.54 million. During the same quarter last year, the firm posted $3.68 earnings per share. The business’s quarterly revenue was up 23.3% on a year-over-year basis.

A number of analysts have recently weighed in on the stock. Zacks Investment Research downgraded shares of United Therapeutics from a “hold” rating to a “sell” rating and set a $192.00 price target for the company. in a research report on Tuesday, July 20th. Argus raised shares of United Therapeutics from a “hold” rating to a “buy” rating and set a $205.00 price target for the company in a research report on Wednesday, July 14th. One research analyst has rated the stock with a sell rating and eight have given a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $220.78.

In other United Therapeutics news, Director Christopher Causey sold 2,610 shares of the firm’s stock in a transaction on Friday, August 6th. The stock was sold at an average price of $210.00, for a total value of $548,100.00. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Paul A. Mahon sold 6,000 shares of United Therapeutics stock in a transaction dated Thursday, September 2nd. The shares were sold at an average price of $210.94, for a total transaction of $1,265,640.00. Following the sale, the executive vice president now owns 42,369 shares in the company, valued at $8,937,316.86. The disclosure for this sale can be found here. In the last ninety days, insiders sold 14,610 shares of company stock valued at $3,038,220. 12.10% of the stock is currently owned by corporate insiders.

Institutional investors have recently modified their holdings of the business. Arizona State Retirement System increased its stake in United Therapeutics by 0.5% in the 1st quarter. Arizona State Retirement System now owns 12,937 shares of the biotechnology company’s stock worth $2,164,000 after purchasing an additional 58 shares in the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS grew its stake in United Therapeutics by 0.4% during the 2nd quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 14,923 shares of the biotechnology company’s stock valued at $2,677,000 after acquiring an additional 63 shares in the last quarter. Rockefeller Capital Management L.P. grew its stake in United Therapeutics by 8.6% during the 1st quarter. Rockefeller Capital Management L.P. now owns 913 shares of the biotechnology company’s stock valued at $152,000 after acquiring an additional 72 shares in the last quarter. GW Henssler & Associates Ltd. grew its stake in United Therapeutics by 2.4% during the 2nd quarter. GW Henssler & Associates Ltd. now owns 3,055 shares of the biotechnology company’s stock valued at $548,000 after acquiring an additional 73 shares in the last quarter. Finally, Banque Cantonale Vaudoise grew its stake in United Therapeutics by 15.3% during the 1st quarter. Banque Cantonale Vaudoise now owns 624 shares of the biotechnology company’s stock valued at $104,000 after acquiring an additional 83 shares in the last quarter. Hedge funds and other institutional investors own 94.95% of the company’s stock.

Shares of UTHR stock traded up $4.63 during mid-day trading on Wednesday, reaching $199.73. 2,801 shares of the company were exchanged, compared to its average volume of 350,693. United Therapeutics has a fifty-two week low of $99.07 and a fifty-two week high of $216.90. The company has a debt-to-equity ratio of 0.22, a quick ratio of 7.15 and a current ratio of 7.44. The company has a market capitalization of $8.97 billion, a P/E ratio of 18.96 and a beta of 0.49. The business’s 50 day simple moving average is $200.58 and its 200 day simple moving average is $191.08.

About United Therapeutics

United Therapeutics Corp. operates as a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening diseases. The firm markets and sells commercial therapies to treat pulmonary arterial hypertension and high-risk neuroblastoma.

Recommended Story: What is a trade deficit?

Get a free copy of the Zacks research report on United Therapeutics (UTHR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.